Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARRIVE: Abatacept in RA with Inadequate Anti-TNF Response
NCT00124982Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2005
- Primary completion
- Aug 2009
- Modality
- Fc-Fusion Proteins
- Countries
- 10
01
Overview
Phase 3, open-label trial of abatacept in rheumatoid arthritis (RA) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Number of Participants With Death, Serious Adverse Events, Related SAEs, SAEs Leading to Discontinuations, AEs, Related AEs, or AEs Leading to Discontinuations at Day 813, Number of Participants With AEs of Special Interest at Day 813 and 3 more. Started Apr 2005; status: completed.
02
Drugs
abatacept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00124982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00124982.